Molecular Psychiatry
September 1, 2024
Brandi Quintanilla, Carlos A. Zarate, Anilkumar Pillai
17 citations
Over 300 million people worldwide suffer from major depressive disorder (MDD). Unfortunately, only 30-40% of patients with MDD achieve complete remission after conventional monoamine antidepressant therapy. In recent years, ketamine has revolutionized the treatment of MDD, with its rapid antidepressant effects manifesting within a few hours as opposed to weeks with conventional antidepressants....
Psychiatry Research
September 1, 2024
Arthur Bezerra Cavalcanti Petrucci, João Vitor Andrade Fernandes, Isabelle Albuquerque Reis et al.
18 citations
We conducted a systematic review and meta-analysis to investigate the comparative effectiveness of ketamine versus electroconvulsive therapy (ECT) for the treatment of major depressive episodes (MDEs). PubMed, EMBASE and Cochrane Library databases were systematically searched for randomized controlled trials (RCTs) comparing ketamine and ECT for MDE. The primary outcome was response rate, for...
Asian Journal of Psychiatry
September 1, 2024
Kaori Ishii, Kyoji Okita
1 citation
In Japan, the landscape of clinical practice for substance use disorder is changing significantly, primarily due to an increase in patients using over-the-counter drugs. A major concern is the rising number of patients misusing dextromethorphan (DXM). These patients with DXM use disorders often have severe trauma-related and mood symptoms, and therefore try to cope with those symptoms by...
The British Journal of Psychiatry
September 1, 2024
Friederike Holze, Peter Gasser, Felix Müller et al.
32 citations
Anxiety disorders are a major public health burden with limited treatment options. We investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness. This study was an a priori-planned long-term follow-up of an investigator-initiated, two-centre trial that used a double-blind,...
Scientific Reports
August 30, 2024
Yumiao Fu, Yifan Song, Yining Li et al.
14 citations
Currently, 280 million people worldwide experience depression, ranking it third in the global burden of disease. The incidence of depression has risen due to the COVID-19 pandemic, making it essential to examine evidence-based practices in reducing depressive symptoms during this unprecedented time. This systematic review and meta-analysis aim to analyze randomized controlled trials during the...
BMJ mental health
August 24, 2024
Shannon Maloney, Merle Kock, Yasmijn Slaghekke et al.
16 citations
Mindfulness-based programmes (MBPs) and practices have demonstrated effects in mental health and well-being, yet questions regarding the target mechanisms that drive change across the population remain unresolved. Five databases were searched for randomised controlled trials that evaluate the indirect effects (IEs) of an MBP or mindfulness practice in relation to mental health and well-being...
Molecular Pharmacology
August 16, 2024
Armida Miranda-Riestra, Montserrat G Cercós, Citlali Trueta et al.
4 citations
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine secreted by the pineal gland during the dark phase of the photoperiod. Its main function is the synchronization of different body rhythms with the dark-light cycle. Research on melatonin has significantly advanced since its discovery and we now know that it has considerable significance in various physiological processes, including...
BMC Psychiatry
August 9, 2024
Roni Chaaya, Chen Jiang, Runtang Meng et al.
Background: The Nightmare Distress Questionnaire (NDQ), known and commonly used for its adequate psychometric properties, is the most widely used instrument for the measurement of nightmare distress. This study aimed to assess the psychometric properties of a newly translated Arabic version of the Nightmare Distress Questionnaire (NDQ-AV). Methods: A total of 546 Lebanese adolescents was...
Journal of Psychopharmacology
August 1, 2024
James Jonathan Rucker, Claire T. Roberts, Mathieu Seynaeve et al.
32 citations
To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), in healthy participants. In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its...
ACS Chemical Neuroscience
August 1, 2024
Samuel C Woodburn, Caleb M. Levitt, Allison M Koester et al.
28 citations
A variety of classic psychedelics and MDMA have been shown to enhance fear extinction in rodent models. This has translational significance because a standard treatment for post-traumatic stress disorder (PTSD) is prolonged exposure therapy. However, few studies have investigated psilocybin's potential effect on fear learning paradigms. More specifically, the extents to which dose, timing of...